Innovita Biological Technology Co. Ltd. A Asset Resilience Ratio
Innovita Biological Technology Co. Ltd. A asset resilience ratio. Innovita Biological Technology Co. Ltd. A (688253) has an Asset Resilience Ratio of 65.12% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 688253 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Innovita Biological Technology Co. Ltd. A (2020–2025)
Asset resilience ratio of Innovita Biological Technology Co. Ltd. A from 2020 to 2025. This chart shows how Innovita Biological Technology Co. Ltd. A's Asset Resilience Ratio has changed over time. Read debt load of Innovita Biological Technology Co. Ltd. for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Innovita Biological Technology Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Innovita Biological Technology Co. Ltd. 's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.45 Billion | 65.12% |
| Total Liquid Assets | CN¥1.45 Billion | 65.12% |
Asset Resilience Insights
- Very High Liquidity: Innovita Biological Technology Co. Ltd. A maintains exceptional liquid asset reserves at 65.12% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Innovita Biological Technology Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Innovita Biological Technology Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
Innovita Biological Technology Co. Ltd. A Asset Resilience Ratio by Year (2020–2025)
Innovita Biological Technology Co. Ltd. A asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Innovita Biological Technology Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 60.75% | CN¥1.38 Billion ≈ $202.27 Million |
CN¥2.28 Billion ≈ $332.96 Million |
-10.86pp |
| 2024-12-31 | 71.61% | CN¥1.58 Billion ≈ $231.84 Million |
CN¥2.21 Billion ≈ $323.75 Million |
-2.49pp |
| 2023-12-31 | 74.10% | CN¥1.53 Billion ≈ $223.97 Million |
CN¥2.07 Billion ≈ $302.27 Million |
+16.72pp |
| 2022-12-31 | 57.38% | CN¥1.11 Billion ≈ $163.11 Million |
CN¥1.94 Billion ≈ $284.26 Million |
+46.44pp |
| 2021-12-31 | 10.93% | CN¥87.25 Million ≈ $12.77 Million |
CN¥797.87 Million ≈ $116.75 Million |
-3.67pp |
| 2020-12-31 | 14.61% | CN¥114.26 Million ≈ $16.72 Million |
CN¥782.09 Million ≈ $114.44 Million |
-- |
About Innovita Biological Technology Co. Ltd. A
Innovita Biological Technology Co., Ltd., a biopharmaceutical enterprise, engages in the research and development, production and sales of POCT rapid diagnostic products. It offers covid-19 test, respiratory disease test, gastrointestinal disease test, fertility test, tropical disease test, and hepatitis test. The company was founded in 2006 and is based in Beijing, China.